Example of Current Gene Therapy format
Recent searches

Example of Current Gene Therapy format Example of Current Gene Therapy format Example of Current Gene Therapy format Example of Current Gene Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Current Gene Therapy format Example of Current Gene Therapy format Example of Current Gene Therapy format Example of Current Gene Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access ISSN: 15665232 e-ISSN: 18755631

Current Gene Therapy — Template for authors

Publisher: Bentham Science
Categories Rank Trend in last 3 yrs
Genetics #139 of 325 down down by 8 ranks
Genetics (clinical) #38 of 87 down down by 1 rank
Drug Discovery #64 of 145 down down by 13 ranks
Molecular Biology #218 of 382 down down by 34 ranks
Molecular Medicine #97 of 167 down down by 17 ranks
journal-quality-icon Journal quality:
Good
calendar-icon Last 4 years overview: 144 Published Papers | 675 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 27/06/2020
Insights & related journals
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Journal Performance & Insights

  • Impact Factor
  • CiteRatio
  • SJR
  • SNIP

Impact factor determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

2.431

10% from 2018

Impact factor for Current Gene Therapy from 2016 - 2019
Year Value
2019 2.431
2018 2.218
2017 1.943
2016 2.78
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 10% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

CiteRatio is a measure of average citations received per peer-reviewed paper published in the journal.

4.7

24% from 2019

CiteRatio for Current Gene Therapy from 2016 - 2020
Year Value
2020 4.7
2019 3.8
2018 4.5
2017 4.6
2016 5.2
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 24% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR) measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

0.704

10% from 2019

SJR for Current Gene Therapy from 2016 - 2020
Year Value
2020 0.704
2019 0.782
2018 1.008
2017 0.951
2016 1.323
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has decreased by 10% in last years.
  • This journal’s SJR is in the top 10 percentile category.

Source Normalized Impact per Paper (SNIP) measures actual citations received relative to citations expected for the journal's category.

0.589

24% from 2019

SNIP for Current Gene Therapy from 2016 - 2020
Year Value
2020 0.589
2019 0.475
2018 0.567
2017 0.515
2016 0.762
graph view Graph view
table view Table view

insights Insights

  • SNIP of this journal has increased by 24% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Related Journals

open access Open Access ISSN: 1756994X
recommended Recommended

Springer

CiteRatio: 15.2 | SJR: 5.564 | SNIP: 2.245
open access Open Access ISSN: 14739542 e-ISSN: 14797364

Springer

CiteRatio: 5.3 | SJR: 1.414 | SNIP: 1.018
open access Open Access ISSN: 15537390 e-ISSN: 15537404
recommended Recommended

PLOS

CiteRatio: 9.0 | SJR: 3.587 | SNIP: 1.457
open access Open Access ISSN: 19375387 e-ISSN: 19375395

Springer

CiteRatio: 4.6 | SJR: 1.028 | SNIP: 1.006

Current Gene Therapy

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Bentham Science

Current Gene Therapy

Current Gene Therapy is an interdisciplinary journal focused on providing the readership with current and comprehensive review articles, original research articles, letters/ short communications and guest edited issues on all aspects of gene therapy. The journal is aimed at al...... Read More

Drug Discovery

Genetics

Genetics(clinical)

Molecular Medicine

Molecular Biology

Pharmacology, Toxicology and Pharmaceutics

i
Last updated on
27 Jun 2020
i
ISSN
1566-5232
i
Impact Factor
High - 1.283
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Yellow faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
Vancouver
i
Citation Type
Numbered
[25]
i
Bibliography Example
Blonder, G E, Tinkham, M, & Klapwijk, T M. Transition from metallic to tunnel- ing regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B. 2013;87(10):100510.

Top papers written in this journal

Journal Article DOI: 10.2174/1566523054065057
New recombinant serotypes of AAV vectors.
Guangping Gao1, Luk H. Vandenberghe, James M. Wilson
31 May 2005 - Current Gene Therapy

Abstract:

AAV based vectors can achieve stable gene transfer with minimal vector related toxicities. AAV serotype 2 (AAV2) is the first AAV that was vectored for gene transfer applications. However, the restricted tissue tropism of AAV and its low transduction efficiency have limited its further development as vector. Recent studies us... AAV based vectors can achieve stable gene transfer with minimal vector related toxicities. AAV serotype 2 (AAV2) is the first AAV that was vectored for gene transfer applications. However, the restricted tissue tropism of AAV and its low transduction efficiency have limited its further development as vector. Recent studies using vectors derived from alternative AAV serotypes such as AAV1, 4, 5 and 6 have shown improved potency and broadened tropism of the AAV vector by packaging the same vector genome with different AAV capsids. In an attempt to search for potent AAV vectors with enhanced performance profiles, molecular techniques were employed for the detection and isolation of endogenous AAVs from a variety of human and non-human primate (NHP) tissues. A family of novel primate AAVs consisting of 110 non-redundant species of proviral sequences was discovered and turned to be prevalent in 18-19% of the tissues evaluated. Phylogenetic and functional analyses revealed that primate AAVs are segregated into clades based on phylogenetic relatedness. The members within a clade share functional and serological properties. Initial evaluation in mouse models of vectors based on these novel AAVs for tissue tropism and gene transfer potency led to the identification of some vector with improved gene transfer to different target tissues. Gene therapy treatment of several mouse and canine models with novel AAV vectors achieved long term phenotypic corrections. Vectors based on new primate AAVs could become the next generation of efficient gene transfer vehicles for various gene therapy applications. read more read less

Topics:

Genetic transfer (53%)53% related to the paper, Tissue tropism (51%)51% related to the paper
465 Citations
open accessOpen access Journal Article DOI: 10.2174/1566523054546224
Altering the tropism of lentiviral vectors through pseudotyping.
James Cronin1, Xian Yang Zhang, Jakob Reiser
31 Jul 2005 - Current Gene Therapy

Abstract:

The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses Such particles possess the tropism of the virus from which the GP was deriv... The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses Such particles possess the tropism of the virus from which the GP was derived For example, to exploit the natural neural tropism of rabies virus, vectors designed to target the central nervous system have been pseudotyped using rabies virus-derived GPs Among the first and still most widely used GPs for pseudotyping lentiviral vectors is the vesicular stomatitis virus GP (VSV-G), due to the very broad tropism and stability of the resulting pseudotypes Pseudotypes involving VSV-G have become effectively the standard for evaluating the efficiency of other pseudotypes This review samples a few of the more prominent examples from the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and host-cell specificity Particular attention is paid to publications of successfully targeting a specific organ or cell types read more read less

Topics:

Pseudotyping (68%)68% related to the paper, Tropism (54%)54% related to the paper, Vesicular stomatitis virus (52%)52% related to the paper
463 Citations
Journal Article DOI: 10.2174/156652307779940216
Meganucleases and DNA double-strand break-induced recombination : Perspectives for gene therapy
31 Jan 2007 - Current Gene Therapy

Abstract:

Meganucleases are sequence-specific endonucleases recognizing large (>12 bp) sequence sites and several laboratories have used these proteins to induce highly efficient gene targeting in mammalian cells. The recent development of artificial endonucleases with tailored specificities has opened the door for a wide range of new ... Meganucleases are sequence-specific endonucleases recognizing large (>12 bp) sequence sites and several laboratories have used these proteins to induce highly efficient gene targeting in mammalian cells. The recent development of artificial endonucleases with tailored specificities has opened the door for a wide range of new applications, including therapeutic ones: redesigned endonucleases cleaving chosen sequences could be used to in gene therapy to correct mutated genes or introduce transgenes in chosen loci. Such "targeted" approaches markedly differ from current gene therapy strategies based on the random insertion of a complementing virus-borne transgene. As a consequence, they should bypass the odds of random insertion. Artificial fusion proteins including Zinc-Finger binding domains have provided important proofs of concept, however the toxicity of these proteins is still an issue. Today custom-designed homing endonucleases, the natural meganucleases, could represent an efficient alternative. After a brief description of the origin of the technology, current systems based on redesigned endonucleases will be presented, with a special emphasis on the recent advances in homing endonuclease engineering. Finally, we will discuss the main issues that will need to be addressed in order to bring this promising technology to the patient. read more read less

Topics:

Homing endonuclease (61%)61% related to the paper, Meganuclease (58%)58% related to the paper, Genome engineering (57%)57% related to the paper, Gene targeting (53%)53% related to the paper
332 Citations
open accessOpen access Journal Article DOI: 10.2174/156652311794520111
Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy.
31 Jan 2011 - Current Gene Therapy

Abstract:

The importance of safer approaches for gene therapy has been underscored by a series of severe adverse events (SAEs) observed in patients involved in clinical trials for Severe Combined Immune Deficiency Disease (SCID) and Chromic Granulomatous Disease (CGD). While a new generation of viral vectors is in the process of replac... The importance of safer approaches for gene therapy has been underscored by a series of severe adverse events (SAEs) observed in patients involved in clinical trials for Severe Combined Immune Deficiency Disease (SCID) and Chromic Granulomatous Disease (CGD). While a new generation of viral vectors is in the process of replacing the classical gamma-retrovirus – based approach, a number of strategies have emerged based on non-viral vectorization and/or targeted insertion aimed at achieving safer gene transfer. Currently, these methods display lower efficacies than viral transduction although many of them can yield more than 1% engineered cells in vitro. Nuclease-based approaches, wherein an endonuclease is used to trigger site-specific genome editing, can significantly increase the percentage of targeted cells. These methods therefore provide a real alternative to classical gene transfer as well as gene editing. However, the first endonuclease to be in clinic today is not used for gene transfer, but to inactivate a gene (CCR5) required for HIV infection. Here, we review these alternative approaches, with a special emphasis on meganucleases, a family of naturally occurring rare-cutting endonucleases, and speculate on their current and future potential. read more read less

Topics:

Genome engineering (57%)57% related to the paper, Genome editing (57%)57% related to the paper, Meganuclease (55%)55% related to the paper, Genetic transfer (54%)54% related to the paper, Viral vector (52%)52% related to the paper
326 Citations
Journal Article DOI: 10.2174/1566523034578285
From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy
Dirk Grimm1, Mark A. Kay
31 Jul 2003 - Current Gene Therapy

Abstract:

Gene transfer vectors based on the human adeno-associated virus serotype 2 (AAV-2) have been developed and tested in pre-clinical studies for almost 20 years, and are currently being evaluated in clinical trials. So far, all these studies have provided evidence that AAV-2 vectors possess many properties making them very attra... Gene transfer vectors based on the human adeno-associated virus serotype 2 (AAV-2) have been developed and tested in pre-clinical studies for almost 20 years, and are currently being evaluated in clinical trials. So far, all these studies have provided evidence that AAV-2 vectors possess many properties making them very attractive for therapeutic gene delivery to humans, such as a lack of pathogenicity or toxicity, and the ability to confer long-term gene expression. However, there is concern that two restrictions of AAV-2 vectors might limit their clinical use in humans. First, these vectors are rather inefficient at transducing some cells of therapeutic interest, such as liver and muscle cells. Second, gene transfer might be hampered by neutralizing anti-AAV-2 antibodies, which are highly prevalent in the human population. In efforts to overcome both limitations, an increasing number of researchers are now focusing on the seven other naturally occurring serotypes of AAV (AAV-1 and AAV-3 to -8), which are structurally and functionally different from AAV-2. To this end, several strategies have been devised to cross-package an AAV-2 vector genome into the capsids of the other AAV serotypes, resulting in a new generation of "pseudotyped" AAV vectors. In vitro and in vivo, these novel vectors were shown to have a host range different from AAV-2, and to escape the anti-AAV-2 immune response, thus underscoring the great potential of this approach. Here the biology of the eight AAV serotypes is summarized, existing technology for pseudotyped AAV vector production is described, initial results from pre-clinical evaluation of the vectors are reviewed, and finally, the prospects of these promising novel tools for human gene therapy are discussed. read more read less

Topics:

Adeno-associated virus (66%)66% related to the paper, Population (53%)53% related to the paper, Gene delivery (52%)52% related to the paper
326 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Current Gene Therapy.

It automatically formats your research paper to Bentham Science formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Current Gene Therapy format uses Vancouver citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

Absolutely not! With our tool, you can freely write without having to focus on LaTeX. You can write your entire paper as per the Current Gene Therapy guidelines and autoformat it.

Yes. The template is fully compliant as per the guidelines of this journal. Our experts at SciSpace ensure that. Also, if there's any update in the journal format guidelines, we take care of it and include that in our algorithm.

Sure. We support all the top citation styles like APA style, MLA style, Vancouver style, Harvard style, Chicago style, etc. For example, in case of this journal, when you write your paper and hit autoformat, it will automatically update your article as per the Current Gene Therapy citation style.

You can avail our Free Trial for 7 days. I'm sure you'll find our features very helpful. Plus, it's quite inexpensive.

Yup. You can choose the right template, copy-paste the contents from the word doc and click on auto-format. You'll have a publish-ready paper that you can download at the end.

A matter of seconds. Besides that, our intuitive editor saves a load of your time in writing and formating your manuscript.

One little Google search can get you the Word template for any journal. However, why do you need a Word template when you can write your entire manuscript on SciSpace, autoformat it as per Current Gene Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Try us out!.

Absolutely! You can do it using our intuitive editor. It's very easy. If you need help, you can always contact our support team.

SciSpace is an online tool for now. We'll soon release a desktop version. You can also request (or upvote) any feature that you think might be helpful for you and the research community in the feature request section once you sign-up with us.

Sure. You can request any template and we'll have it up and running within a matter of 3 working days. You can find the request box in the Journal Gallery on the right sidebar under the heading, "Couldn't find the format you were looking for?".

After you have written and autoformatted your paper, you can download it in multiple formats, viz., PDF, Docx and LaTeX.

To be honest, the answer is NO. The impact factor is one of the many elements that determine the quality of a journal. Few of those factors the review board, rejection rates, frequency of inclusion in indexes, Eigenfactor, etc. You must assess all the factors and then take the final call.

SHERPA/RoMEO Database

We have extracted this data from Sherpa Romeo to help our researchers understand the access level of this journal. The following table indicates the level of access a journal has as per Sherpa Romeo Archiving Policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

The 5 most common citation types in order of usage are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

Our journal submission experts are skilled in submitting papers to various international journals.

After uploading your paper on SciSpace, you would see a button to request a journal submission service for Current Gene Therapy.

Each submission service is completed within 4 - 5 working days.

Yes. SciSpace provides this functionality.

After signing up, you would need to import your existing references from Word or .bib file.

SciSpace would allow download of your references in Current Gene Therapy Endnote style, according to bentham-science guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Current Gene Therapy formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template